• On September 18, 2025, IDEX Corporation's board approved its 124th consecutive quarterly cash dividend of US$0.71 per share, to be paid on October 24, 2025, and increased its share repurchase program by US$650 million, lifting the total buyback authorization to US$2.51 billion.
• IDEX’s expanded buyback plan highlights a robust commitment to shareholder returns and confidence in its financial position amid ongoing sector and policy uncertainties.
• We'll explore how IDEX’s significant boost to its share repurchase authorization may influence its long-term investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

IDEX Investment Narrative Recap

To own IDEX stock, investors generally need to believe in the company's long-term ability to tap into growth sectors such as space, defense, and energy transition, while navigating challenges like sector cyclicality and policy uncertainty. The recently expanded US$2.51 billion buyback program and continued dividends demonstrate management’s confidence, but these capital return moves are not expected to meaningfully impact near-term earnings volatility tied to weaker demand in sectors like chemicals and agriculture.

Of the recent announcements, the updated quarterly dividend remains the most relevant to this news. IDEX’s uninterrupted dividend streak, now at 124 consecutive quarters, underlines its commitment to steady shareholder returns, even as organic sales pressures and hesitancy for larger projects continue to weigh on revenue forecasts and investor sentiment.

However, investors should also be mindful that even with these positive signals, revenue stability could be tested by...

IDEX's outlook anticipates $4.0 billion in revenue and $698.2 million in earnings by 2028. This is based on a 6.4% annual revenue growth rate and an increase in earnings of $228.8 million from the current $469.4 million.

Uncover how IDEX's forecasts yield a $194.62 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Three individual fair value estimates from the Simply Wall St Community range dramatically from as low as US$15 to over US$265 per share. While community perspectives vary widely, ongoing tariff-driven cost pressures remain a concern for those evaluating IDEX’s long-term profit resilience and future share price performance.

Explore 3 other fair value estimates on IDEX - why the stock might be worth less than half the current price!

Build Your Own IDEX Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your IDEX research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free IDEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEX's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.